Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a ...

Regeneron is also expanding its Tarrytown, New York-based facility and building a separate facility in the state to expand capacity to fill injection pens - a process known as fill-finish. Its ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.

TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: The sessions may be accessed from the ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...

Regeneron (REGN) is expected to deliver a ... price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth ...